Vaccines, Blood & Biologics
Telecon, August 3, 2011 - HPC Cord Blood
RECORD OF TELEPHONE CONVERSATION
Submission Type: BLA Submission ID: 125391/0 Office: OCTGT
Hematopoietic Progenitor Cells,Cord (HPC-C)
Telecon Date/Time: 03-Aug-2011 12:00 AM Initiated by FDA? Yes
Telephone Number: -----(b)(4)-----
Author: RAMANI SISTA
The Sponsor requested clarification for some of the requests made in the 74 day letter.
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Following introductions, the Sponsor requested clarification for some of the requested information included in the 74 day letter of July 3, 2011. These are:
Regarding Integrity testing, the Sponsor stated they use ------------(b)(4)------------ to test bag integrity and requested clarification as to FDA requirements. FDA stated as an end user the Sponsor is not required to perform integrity tests provided that the containers are FDA cleared and/or approved. If you decide to perform a test to demonstrate the container’s integrity, you are expected to use a more sensitive method, for example using staining method, involving filling the bag with colored liquid, and testing for leakage.
The Sponsor stated that they were confused with the request for information in the 74 day letter of July 14, 2011 regarding request for validation information for older units. FDA stated that this request was just a confirmation of the Sponsor’s understanding on units they planned to license. FDA reiterated that the best approach is to request licensure for recent units and after inspection and approval of their BLA; they could submit a supplement with request for licensure for older units. If the sponsor’s intention is to license the prospective inventory only then they do not need to submit information of the older unit.
FDA provided detailed explanations to the Sponsor regarding validation, retrospective validation, and Master Batch records.